The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 41 | 37.0x | 20.1x | Near average | |
Growth | 43 | 7.8% | 5.6% | Near average | |
Quality | 72 | 11.1% | 7.6% | Above average | |
Safety | 46 | 5.2x | 0.4x | Near average | |
Capital Return | 33 | 1.25% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Royalty Pharma plc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Royalty Pharma plc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Royalty Pharma stock shows a state of complete stability in analyst estimates during recent periods (1, 7, and 30 days), as the average price target settled at 53.75 dollars without any significant adjustments. Notably, the stock is currently trading at 54.5 dollars, a level that exceeds the Consensus and the Median price, suggesting that the stock may have exhausted its expected upward momentum according to current estimates.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.